Cutaneous Squamous Cell Carcinoma (cSCC) Market Insights, Epidemiology and Market Forecasts, 2016-2018 & 2027

DUBLIN, Jan. 24, 2019 /PRNewswire/ --

The "Cutaneous Squamous Cell Carcinoma (cSCC) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

Cutaneous Squamous Cell Carcinoma (cSCC) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cutaneous Squamous Cell Carcinoma (cSCC) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cutaneous Squamous Cell Carcinoma (cSCC) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Cutaneous Squamous Cell Carcinoma (cSCC) - Disease Understanding and Treatment Algorithm

Cutaneous squamous cell carcinoma (cSCC), is defined as a malignant proliferation of cutaneous epithelium, which indicates 20% to 50% of skin cancers .cSCC is associated with more mutations than other common malignancies-5 times the mutation rates in lung cancer and >4 times the mutation rates in melanoma as per the Que SKT et. al. 2018.

Unlike almost all basal-cell carcinomas, cutaneous squamous cell carcinomas are associated with a substantial risk of metastasis. The prognosis is favorable and only 2-5% of SCC metastasize.

Exposure to cancer-promoting stressors and the response of the body to those exposures (host response) promote the development of cSCC. Well-known risk factors include the following: UVR exposure, Immunosuppression, Exposure to ionizing radiation or chemical carcinogens, Human papillomavirus (HPV) infection.

The Cutaneous Squamous Cell Carcinoma (cSCC) market report gives the thorough understanding of the Cutaneous Squamous Cell Carcinoma (cSCC) by including details such as disease definition, symptoms, classification, causes, genetics and inheritance, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cutaneous Squamous Cell Carcinoma (cSCC) in the US, Europe, and Japan.

Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology
The Cutaneous Squamous Cell Carcinoma (cSCC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC), Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC), Gender Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC), and Diagnosed and treatable Cases of Cutaneous Squamous Cell Carcinoma (cSCC)] scenario of Cutaneous Squamous Cell Carcinoma (cSCC), in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

As per Talib Najjar et. Al. Cutaneous Squamous Cell Carcinoma (cSCC) is one of the most common cancers overall in the United States. An estimated 3.5 million cases of nonmelanoma skin cancers were diagnosed in the United States in 2006; of those, approximately 80% were basal cell carcinoma (BCC) and 20% were cSCC.

According to Syril Keena T et. Al., the age-standardized incidence of cSCC ranges from 9 to 96 per 100,000 male inhabitants and 5 to 68 per 100,000 female inhabitants (2002-2007 estimates).

As per Burton KA et. Al. cSCC is diagnosed at a rate of 15-35 per 100,000 people and is expected to increase 2-4 % per year. With respect to metastatic cSCC, this disease is more common in men; people over the age of 75 years; and inhabitants of the south and mid-west USA.

This research estimates that the incident population of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM will significantly change during the study period [2016-2027].

Cutaneous Squamous Cell Carcinoma (cSCC) Drug Chapters

This segment of the Cutaneous Squamous Cell Carcinoma (cSCC) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Most Cutaneous Squamous Cell Carcinomas (cSCC) are removed via surgery or radiation therapy and, a few selective cases that are not eligibile for surgery or radiation, are treated with topical medication i.e., off-label chemotherapeutic agents like 5-Fluorouracil, EGFR inhibitors, and Antimicrotubular agents, etc.

At Present, the only FDA approved therapy for the treatment of Cutaneous Squamous Cell Carcinomas (cSCC) is Cemiplimab (Regeneron Pharmaceuticals). So, the current therapeutic market of cSCC is occupied by Regeneron's product and the above-mentioned off-label therapies.

Key players such as Vidac Pharma, Amgen, Merck & Co., and many others are involved in developing therapies for Cutaneous Squamous Cell Carcinoma. Expected launch of emerging therapies such as Talimogene laherparepvec (Amgen), VDA-1102 (Vidac Pharma) and Pembrolizumab (Merck Sharp & Dohme) and other compelling treatments, are expected to change the treatment landscape of Cutaneous Squamous Cell Carcinoma in upcoming years.

Cutaneous Squamous Cell Carcinoma (cSCC) Market Outlook

The Cutaneous Squamous Cell Carcinoma (cSCC) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM is expected to change from 2016-2027.

Key Topics Covered:

1. Report Introduction

2. Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview at a Glance
2.1. 7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in 2017
2.2. 7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in 2027

3. Disease Background and Overview: Cutaneous Squamous Cell Carcinoma (cSCC)
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis

4. Epidemiology and Patient Population
4.1. 7MM Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
4.2. 7MM Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
4.3. 7MM Gender Specific Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
4.4. 7MM Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
4.5. 7MM Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)

5. Cutaneous Squamous Cell Carcinoma: Country- Wise Epidemiology

6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Marketed drug
7.1.1. Cemiplimab: Regeneron Pharmaceuticals
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Advantages & Disadvantages
7.1.5. Safety and Efficacy
7.1.6. Product Profile

8. To be continued in the report

9. Emerging Therapies
9.1. Key Cross Competition
9.1.1. Talimogene laherparepvec: Amgen
9.1.2. Regulatory Milestones
9.1.3. Clinical Development
9.1.4. Product Profile
9.1.5. Clinical Pipeline Activity
9.1.6. Pembrolizumab: Merck Sharp & Dohme

10. To be continued in report

11. Cutaneous Squamous Cell Carcinoma Market Size
11.1. Key Findings
11.2. Total 7MM Cutaneous Squamous Cell Carcinoma (cSCC) Market Analysis
11.2.1. Overview of Total Cutaneous Squamous Cell Carcinoma (cSCC) Market
11.2.1.1. Market size of Cutaneous Squamous Cell Carcinoma (cSCC) Market by 7MM (2016-2027)

12. 7MM: Country-Wise Market Analysis

13. Market Drivers

14. Market Barriers

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/b35p4v/cutaneous?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com